S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
NASDAQ:ACET

Adicet Bio Stock Forecast, Price & News

$10.64
+1.12 (+11.76%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.54
$10.77
50-Day Range
$7.01
$10.64
52-Week Range
$6.25
$17.80
Volume
267,724 shs
Average Volume
129,037 shs
Market Capitalization
$340.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.36
30 days | 90 days | 365 days | Advanced Chart
Receive ACET News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.


Adicet Bio logo

About Adicet Bio

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Headlines

Adicet Bio (NASDAQ:ACET) Receives "Buy" Rating from JMP Securities
November 15, 2021 |  americanbankingnews.com
CDR-Life Announces Expansion of Scientific Advisory Board
October 26, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Sector
Medical
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
82
Year Founded
N/A

Sales & Book Value

Annual Sales
$17.90 million
Book Value
$5.58 per share

Profitability

Net Income
$-36.68 million
Pretax Margin
-572.82%

Debt

Price-To-Earnings

Miscellaneous

Free Float
21,122,000
Market Cap
$340.00 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.17 out of 5 stars

Medical Sector

398th out of 1,390 stocks

Pharmaceutical Preparations Industry

183rd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Adicet Bio (NASDAQ:ACET) Frequently Asked Questions

Is Adicet Bio a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Adicet Bio stock.
View analyst ratings for Adicet Bio
or view top-rated stocks.

How has Adicet Bio's stock been impacted by Coronavirus?

Adicet Bio's stock was trading at $0.1345 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACET shares have increased by 7,810.8% and is now trading at $10.64.
View which stocks have been most impacted by COVID-19
.

When is Adicet Bio's next earnings date?

Adicet Bio is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Adicet Bio
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 10th. The company reported ($0.44) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.44). The company had revenue of $3.43 million for the quarter, compared to analyst estimates of $4.65 million.
View Adicet Bio's earnings history
.

What price target have analysts set for ACET?

6 Wall Street analysts have issued 12-month price objectives for Adicet Bio's shares. Their forecasts range from $22.00 to $34.00. On average, they anticipate Adicet Bio's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 172.6% from the stock's current price.
View analysts' price targets for Adicet Bio
or view top-rated stocks among Wall Street analysts.

Who are Adicet Bio's key executives?

Adicet Bio's management team includes the following people:
  • Chen Schor, President, CEO, Secretary & Director (LinkedIn Profile)
  • Brian Nicholas Harvey, Chief Financial Officer
  • Francesco Galimi, Chief Medical Officer & Senior Vice President
  • Donald Healey, Chief Technology Officer
  • Blake Aftab, Chief Scientific Officer & Senior Vice President

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include (MRIN), FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

What is Adicet Bio's stock symbol?

Adicet Bio trades on the NASDAQ under the ticker symbol "ACET."

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (4.00%), BlackRock Inc. (3.92%), Johnson & Johnson (2.28%), Geode Capital Management LLC (1.07%), 683 Capital Management LLC (0.83%) and Granite Point Capital Management L.P. (0.62%). Company insiders that own Adicet Bio stock include Aya Jakobovits, Chen Schor and Jay P Elliott.
View institutional ownership trends for Adicet Bio
.

Which institutional investors are selling Adicet Bio stock?

ACET stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Renaissance Technologies LLC, Two Sigma Advisers LP, Granite Point Capital Management L.P., California State Teachers Retirement System, Dimensional Fund Advisors LP, and New York State Common Retirement Fund. Company insiders that have sold Adicet Bio company stock in the last year include Aya Jakobovits, Chen Schor, and Jay P Elliott.
View insider buying and selling activity for Adicet Bio
or view top insider-selling stocks.

Which institutional investors are buying Adicet Bio stock?

ACET stock was acquired by a variety of institutional investors in the last quarter, including Johnson & Johnson, 683 Capital Management LLC, Point72 Asset Management L.P., Kingdon Capital Management L.L.C., Goldman Sachs Group Inc., Geode Capital Management LLC, Deutsche Bank AG, and Golden State Equity Partners.
View insider buying and selling activity for Adicet Bio
or or view top insider-buying stocks.

How do I buy shares of Adicet Bio?

Shares of ACET can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adicet Bio's stock price today?

One share of ACET stock can currently be purchased for approximately $10.64.

How much money does Adicet Bio make?

Adicet Bio has a market capitalization of $340.00 million and generates $17.90 million in revenue each year. The company earns $-36.68 million in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Adicet Bio have?

Adicet Bio employs 82 workers across the globe.

What is Adicet Bio's official website?

The official website for Adicet Bio is www.aceto.com.

Where are Adicet Bio's headquarters?

Adicet Bio is headquartered at 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050.

How can I contact Adicet Bio?

Adicet Bio's mailing address is 4 TRI HARBOR COURT, PORT WASHINGTON NY, 11050. The company can be reached via phone at (857) 315-5528 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.